The Epidermal Growth Factor Receptor: A Potential Therapeutic Target in Chronic Kidney Disease

Authors

  • Zijun Liu, MD, PhD Nanjing First Hospital, Nanjing Medical University, Nanjing, China
  • Na Liu, MD, PhD Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
  • Shi-Bin Cheng, MD, PhD Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA Chronic kidney disease (CKD) is a clinical syndrome characterized by a gradual loss of kidney function that persists for >3 months with health implications and affects nearly 500 million people worldwide. Diabetes and hypertension are the 2 most common causes of CKD, which account for up to two-thirds of the cases.

DOI:

https://doi.org/10.17140/NPOJ-3-e006

Keywords:

oxidative, hyperuricemia, demonstrate

Abstract

Chronic kidney disease (CKD) is a clinical syndrome characterized by a gradual loss
of kidney function that persists for >3 months with health implications and affects nearly 500
million people worldwide. Diabetes and hypertension are the 2 most common causes of CKD,
which account for up to two-thirds of the cases.1-3 Accumulating evidence has shown that hyperuricemia is tightly associated with the pathogenesis of CKD.1-4 Hyperuricemic nephropathy is
a condition characterized by glomerular hypertension, arteriolosclerosis, and tubule interstitial
fibrosis. Prior studies demonstrate that decreasing uric acid levels delays the development of
CKD and slows its progression and uric acid is an independent predictor of future development
of CKD.1-4 The mechanistic processes by which hyperuricemia induces chronic renal injury
involve deposition of uric acid crystals in the collecting duct of the kidney, renal angiotension
system activation, oxidative stress, tubular epithelial cell transition and inflammation.4-7

References

Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009; 53(5): 796-803. doi: 10.1053/j.ajkd.2008.12.021

Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011; 33(4): 352-357. doi: 10.1159/000326848

Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: The severance cohort study. Nephrol Dial Transplant. 2012; 27(5): 1831-1835. doi: 10.1093/ndt/gfr530

Liu N, Wang L, Yang T, et al. EGF receptor inhibition alleviates hyperuricemic nephropathy. J Am Soc Nephrol. 2015; 26(11): 2716-2729. doi: 10.1681/ASN.2014080793

Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mecha-nism. Hypertension. 2001; 38(5): 1101-1106. doi: 10.1161/hy1101.092839

Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013; 304(5): F471-F480. doi: 10.1152/ajprenal.00560.2012

Umekawa T, Chegini N, Khan SR. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol Dial Transplant. 2003; 18(4): 664-669. doi: 10.1093/ndt/gfg140

Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transac-tivation of the epidermal growth factor receptor. Steroids. 2008; 73(9-10): 870-873. doi: 10.1016/j.steroids.2007.12.025

Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002; 80(2): 231-238.

Chen J, Chen JK, Nagai K, et al. EGFR signaling promotes TGFβ-dependent renal fibrosis. J Am Soc Nephrol. 2012; 23(2): 215- 224. doi: 10.1681/ASN.2011070645 Nephrol Open J Page e2

Downloads

Published

2016-09-08

How to Cite

Zijun Liu, MD, PhD, Na Liu, MD, PhD, & Shi-Bin Cheng, MD, PhD. (2016). The Epidermal Growth Factor Receptor: A Potential Therapeutic Target in Chronic Kidney Disease. Nephrology, 1–2. https://doi.org/10.17140/NPOJ-3-e006

Issue

Volume 3 Issue 1 2017

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.

Most read articles by the same author(s)